SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as the community discusses its potential, noting a recent price pump and increased trading volume. Some speculate about the catalyst behind the movement, while others point to cross-chain analysis indicating potential whale accumulation. Despite the positive price action, skepticism remains due to ICP's past performance and concerns about its tokenomics.

Grindr, Inc. engages in the operation of a social media network application for the gay, bi, trans, queer, and other members of the LGBTQ+ community. The company was founded in 2009 and is headquartered in West Hollywood, CA.

Grindr Inc - Ordinary Shares - Class A

Grindr Inc

Grindr is trending due to buyout speculation, with major shareholders proposing a take-private deal at $18 per share, creating significant community buzz around a potential near-term return. Discussions also involve the possibility of short squeezes given the stock's high short interest. Some traders are weighing in on whether minority shareholders will get a fair deal.

zkSync

ZK is trending as community members discuss its potential, particularly after the delivery of Atlas. Bullish sentiment seems to be building, with some eyeing key resistance levels and anticipating further upside for the project. Recent developments around ZK-tech, enterprise solutions, and compiler updates are also driving interest.

Peloton Interactive, Inc. provides an at-home fitness platform for live and on-demand indoor cycling classes. The firm pioneered connected, technology-enabled fitness, and the streaming of immersive, instructor-led boutique classes for its members. It operates through the Connected Fitness Products and Subscription segments. The Connected Fitness Products segment includes the sales of bikes, tread & related accessories. The Subscription segment refers to the monthly subscription and credits from live studio classes. The company was founded by John Foley, Graham Stanton, Thomas Cortese, Yony Feng, and Hisao Kushi in 2012 and is headquartered in New York, NY.

Peloton Interactive Inc - Ordinary Shares - Class A

Peloton Interactive Inc

Peloton is trending as analysts turn bullish following recent financial results and upgrades from Goldman Sachs and Macquarie, with community members discussing potential for a turnaround. Speculation includes possible AI integration and a potential short squeeze, with some comparing PTON's potential to Carvana's comeback. However, others remain skeptical, citing a challenging macroeconomic environment and past disappointments.

Optimism is more than just a single blockchain – it's a growing network of chains called the Superchain, all built on the open-source OP Stack. While OP Mainnet was the first, many prominent chains now run on the Optimism’s OP Stack, including Base (by Coinbase), Unichain (by Uniswap), Ink (by Kraken), and World Chain (by Worldcoin). The OP Stack has become the leading framework for Ethereum Layer 2 chains, powering the majority of L2 activity today. Every OP Chain in the Superchain contributes back to the Optimism Collectiv and all chains follow a standardized revenue-sharing model: the greater of 2.5% of total chain revenue or 15% of onchain profit (defined as fees minus L1 gas costs) is paid back to the Optimism. By aligning economic incentives across many chains, Optimism transforms Ethereum scaling into a sustainable flywheel by delivering fast, low-cost transactions while reinvesting in the future of the ecosystem. OP holders participate in governance to shape protocol upgrades, funding decisions, and more.

Optimism Coin

Optimism Coin is trending as investors discuss its potential as a major retail squeeze candidate, while some traders are shorting, anticipating a collapse following the FOMC meeting. Community members are actively debating whether altcoins are dead while also assessing the impact of news such as the NEAR Foundation partnership on price movements.

Sprott Physical Platinum and Palladium Trust - Unit

Sprott Physical Platinum & Palladium

SPPP is trending as precious metals and the materials sector gain momentum, with platinum and palladium potentially outperforming gold and silver. The community is closely watching for breakouts and discussing the potential for a commodity super cycle. Some investors believe SPPP represents a compelling opportunity, given the limited supply and increasing demand for platinum and palladium in catalytic converters and other industrial applications.

International Flavors & Fragrances, Inc. engages in the manufacture and supply of flavors and fragrances used in the food, beverage, personal care, and household products industries. It operates through the following segments: Nourish, Health & Biosciences, Scent and Pharma Solutions. The Nourish segment consists of legacy Taste segment combined with N&B's Food & Beverage division and the food protection business of N&B's Health & Biosciences division. The Health & Biosciences business consists of a biotechnology-driven portfolio of enzymes, food cultures, probiotics and specialty ingredients for food, home and personal care, and health and wellness applications. The Scent business creates fragrance compounds, fragrance ingredients and cosmetic ingredients that are integral elements in the world’s finest perfumes and best-known household and personal care products. The Pharma Solutions business produces a vast portfolio including cellulosics and seaweed-based pharma excipients, used to improve the functionality and delivery of active pharmaceutical ingredients, including controlled or modified drug release formulations, and enabling. The company was founded in 1833 and is headquartered in New York, NY.

International Flavors & Fragrances Inc.

IFF is trending due to upcoming Q3 earnings report, with mixed expectations as solid segment performance faces potential margin squeeze from rising costs; analysts are weighing in with updated ratings and price targets. The community is actively discussing option strategies and potential ROI, with some seeing a longer-term value opportunity supported by a stable dividend and potential for operational efficiency. Recent news includes strategic partnerships, product launches, and insider activity.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

BHVN is trending as investors discuss its potential as a squeeze candidate and analyze options activity, particularly call buying. The community is focused on upcoming catalysts, including the FDA's PDUFA review for troriluzole in Q4 2025, with discussion around potential approval and market impact. Some traders are weighing the impact of a possible government shutdown on FDA timelines.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

TERN is trending as the community discusses its potential as a buyout candidate and strategic restructuring after a recent discontinuation of metabolic programs. Despite the setback in its obesity program, the stock price has seen improvement, leading to speculation about a potential acquisition or licensing deal. Investors are also monitoring upcoming trial data for its CML program as a key catalyst.

Listed Funds Trust - Teucrium 2x Long Daily XRP ETF

The Teucrium 2x Long Daily XRP ETF

The Teucrium 2x Long Daily XRP ETF ($XXRP) is trending as traders discuss its potential for amplified gains relative to XRP, particularly with upcoming catalysts like potential regulatory clarity and spot ETF approvals. Community members are actively trading the ETF, with some citing substantial profits and accumulating shares during dips, while others express concerns about its tracking accuracy and decay over time. Speculation is also rising around potential price targets, trading strategies, and its long-term investment viability within the broader context of the crypto market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues

Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.

Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +7.77% and +27.69%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia

Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.

Agios Pharmaceuticals, Inc. (AGIO) announced on Thursday that the U.S. Food and Drug Administration has extended the review period for its drug Pyrukynd, intended for the treatment of adult patients with thalassemia, by three months.Thalassemia is a rare, inherited blood disease that affects the production of the protein hemoglobin in red blood cells. By disrupting hemoglobin production, thalassemia reduces the number of circulating red blood cells and shortens their lifespan, resulting in anemia, fatigue, and severe complications.While the FDA was initially expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.agios.com/news-releases/news-release-details/agios-provides-update-us-pdufa-goal-date-pyrukyndr-mitapivat">expected</a> by December 7. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AGIO">AGIO stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:585/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_04_at_10_30_42_AM_png_307a186918.webp" alt="AGIO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on Sept. 4, 2025 | Source: Stocktwits" width="585" height="62"><figcaption>AGIO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on Sept. 4, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that these are circumstances beyond the company's control.<stembedurl>https://stocktwits.com/forprofit12/message/627455227</stembedurl>A pessimistic user, however, called for selling the company's shares.<stembedurl>https://stocktwits.com/Jadek6/message/627455837</stembedurl>In the original application, the company had described the risk of hepatocellular injury with the drug. However, the firm stated on Thursday that it has submitted a proposed Risk Evaluation and Mitigation Strategy (REMS) in response to a recent information request from the agency.The extension in date of the FDA’s decision is not the result of new or additional efficacy or safety data requested by the FDA or submitted by Agios, but a result of the new REMS submission, the company said. It further termed the REMS submission a major amendment to its original application.“We remain confident in the favorable benefit-risk profile of PYRUKYND in thalassemia,” said CEO Brian Goff. &nbsp;As per Agios, approximately 6,000 adult patients are diagnosed with thalassemia in the U.S.BofA subsequently lowered its price target on Agios Pharmaceuticals to $51 from $52 while keeping a ‘Buy’ rating on the shares. The firm noted that the extension was not the result of new data requested by the FDA or submitted by the company. BofA still views approval in thalassemia as likely given its key opinion leader checks and the strength of data from late-stage trials supporting the application. As such, Agios remains one of the firm's top picks even with the delay, it said.Pyrukynd is already approved for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. Pyruvate kinase (PK) deficiency is a rare, inherited disorder causing chronic hemolytic anemia in adults, where red blood cells break down too quickly due to a lack of the PK enzyme, resulting in low red blood cell count.AGIO stock is up by 6% this year but down by over 22% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/fda-says-no-advisory-commitee-meeting-required-for-aquestive-oral-epinephrine-film/chwd20pRdYB">FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More 

While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7. 

Equity

Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Retail chatter around Agios Pharmaceuticals spiked Tuesday after the company said that Saudi Arabia’s Food and Drug Authority (SFDA) approved Pyrukynd (mitapivat) for the treatment of adult patients with alpha- or beta-thalassemia, regardless of transfusion status.The approval was granted under the SFDA’s Breakthrough Medicines Program and is based on results from the global Energize and Energize-T Phase 3 trials.&nbsp;<a href="https://stocktwits.com/symbol/AGIO">Shares of Agios Pharmaceuticals</a> closed 3.3% higher at $36.16 on Monday, with the stock rising another 2% in after-hours trading to $36.88.Agios had partnered with NewBridge Pharmaceuticals in 2024 to support regional commercialization efforts across the Gulf Cooperation Council (GCC), including the UAE, Kuwait, Qatar, Oman, and Bahrain.However, the milestone approval came alongside new safety scrutiny in the U.S. market.&nbsp;Leerink analyst Andrew Berens noted that three newly listed deaths involving Pyrukynd appeared in the FDA’s Adverse Event Reporting System (FAERS) in July, bringing the total to four since launch.Two of the July cases were in young patients. Berens called the developments “potentially concerning” but cautioned that FAERS entries often lack key details and context.In a regulatory filing, Agios said it was aware of the report and confirmed that three of the four cases had already been submitted to the FDA through standard pharmacovigilance processes.&nbsp;Two patients involved&nbsp;were treated with Pyrukynd for pyruvate kinase deficiency under its approved U.S. indication, while one patient with sickle cell disease&nbsp;was treated through expanded access.&nbsp;The fourth case had been reported directly to the FDA, and Agios said it is currently evaluating it.The company added that, to date, the available information does not change Pyrukynd’s benefit-risk profile as represented in its U.S. prescribing information.A regulatory decision on Pyrukynd for thalassemia is due from the U.S. FDA by Sept. 7. Additional filings are under review in the UAE and European Union.On Stocktwits, retail sentiment for Agios was ‘bullish’ amid ‘extremely high’ message volume.One user acknowledged not being bullish on the stock but noted that each reported death involved patients with severe underlying conditions.&nbsp;“Two were dealing with sickle cell complications, one was 93 and already critically ill — none were stable patients simply adding Pyrukynd to an existing regimen,” the user wrote, suggesting the outcomes may not reflect typical treatment scenarios.&nbsp;<stembedurl>https://stocktwits.com/Dkll303/message/623704770</stembedurl>Another user focused on the day’s sharp intraday recovery, and said the stock had an “absolutely incredible recovery.”<stembedurl>https://stocktwits.com/yachtsandthots/message/623705222</stembedurl>Agios’ stock has risen 13.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter around Agios Pharmaceuticals (AGIO) spiked Tuesday after the company said that Saudi Arabia’s Food and Drug Authority (SFDA) approved Pyrukynd. (Photo credit: Getty Images)

Agios Retail Buzz Surges On Saudi Thalassemia Nod As Retail Hails ‘Incredible Recovery’ Despite FDA Concerns

Retail investors defended Agios on Stocktwits, saying reported deaths involved critically ill patients and didn’t reflect typical use. 

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -10.92% and +34.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

AGIO
Agios Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AGIO News

AGIOAgios Pharmaceuticals Inc